Mild hidradenitis suppurativa is often treated with cycles of steroids and antibiotics that have adverse effects. Can an anti ...
Dismissal of care priorities rather than cultural context is the greatest barrier to proper wound care among Latine patients ...
Differentiating tunnel and abscess/inflammatory nodule recurrence refines surgical outcomes after wide excision in patients ...
Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...
Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Applic ...
Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...
Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative ...
Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA- , povorcitinib, ILUMYA®, ODOMZO- , REMICADE- , ...
Zacks Investment Research on MSN
KYMR skyrockets 82.4% in a year: More upside potential in 2026?
Kymera Therapeutics, Inc. KYMR has put up a stupendous performance over the past year. Shares of this clinical-stage ...
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has named Vimal Patel, PharmD, as senior vice president of medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback